Download PDF
Nervenheilkunde 2005; 24(07): 557-572
DOI: 10.1055/s-0038-1629999
Original Article
Schattauer GmbH

„Ecstasy“ – die Droge der Techno-Generation

Klinische Aspekte“Ecstasy” - the drug of the techno generationClinical aspects
R. W. Freudenmann
1   Abt. Psychiatrie III der Universitätsklinik Ulm (Leiter: Prof. Dr. Dr. M. Spitzer)
› Author Affiliations
Further Information

Publication History

Publication Date:
25 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Die vorliegende Arbeit liefert eine Einführung zu „Ecstasy“, der Modedroge der Techno-Musik-Generation. Der Schwerpunkt liegt auf klinisch relevanten Informationen. „Ecstasy“ ist der Straßenname für das ring-substituierte Amphetaminderivat 3,4-Methylene-Dioxy-Methamphetamin, kurz MDMA. Mittlerweile wird der Name „Ecstasy“ als Sammelbegriff für MDMA und seine chemisch nur leicht abweichenden Analoga MDA, MDEA und MBDB verwendet. Ausgehend von der Chemie wird der molekulare Wirkmechanismus der Substanzen erläutert. Die psychotropen und peripheren Wirkungen von „Ecstasy“ samt Komplikationen und das Vorgehen bei Intoxikationen werden dargestellt. Zudem werden die wichtigsten pharmakokinetischen Eigenschaften und gefährliche Wechselwirkungen mit anderen Substanzen besprochen. Typische Gebrauchsmuster, neue epidemiologische Gesichtspunkte und juristische Aspekte dieser in Deutschland nicht-verkehrsfähigen Betäubungsmittel werden beschrieben. Abschließend werden mögliche Langzeitfolgen beim Menschen nach schwerem „Ecstasy“-Konsum diskutiert.

Summary

This paper provides an introduction to “Ecstasy”, the most popular abused drug of the techno music generation. It focuses on information for clinical purposes. „Ecstasy“ is the street name for the ring-substituted amphetamine derivate 3,4-methylene-dioxy-methamphetamine (MDMA). Today, the name “Ecstasy” is used as a group name for MDMA and its close chemical analogs MDA, MDEA and MBDB. Starting from their chemistry their molecular mechanism of action is described. Central nervous and somatic effects of “Ecstasy” including complications and therapeutic measures after intoxikation are described. In addition, we illustrate the most important aspects of pharmacokinetic and interactions with other substances. We also explain typical patterns of substance use, new epidemiological trends and legal issues. Finally, possible long-term effects in humans resulting from severe “Ecstasy” use are discussed.

Schlüsselwörter

Ecstasy - MDMA - Amphetamin-Derivate - Designer-Drogen

Key words

Ecstasy - MDMA - amphetamine derivates - designer drugs
 

  • Literatur

  • 1 Kalant H. The pharmacology and toxicology of „ecstasy“ (MDMA) and related drugs. Can Med Assoc J 2001; 165: 917-28.
    Google Scholar
  • 2 Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001; 16: 557-77.
    CrossrefPubMedGoogle Scholar
  • 3 Ricaurte GA. et al. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. Jama 1988; 260: 51-5.
    CrossrefPubMedGoogle Scholar
  • 4 Ricaurte G, Bryan G, Strauss I, Seiden I, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986-8.
    CrossrefPubMedGoogle Scholar
  • 5 World Health Organization. Amphetamine like stimulants. Report from the WHO meeting on amphetamines, MDMA and other psychostimulants. November 1996 Geneva: WHO; 1996: 6.
    Google Scholar
  • 6 Freudenmann RW, Spitzer M. The neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev 2004; 10: 89-116.
    PubMedGoogle Scholar
  • 7 Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Sass H. Die Entaktogene „Ecstasy“ (MDMA), „Eve“ (MDE) und andere ringsubstituierte Methamphetaminderivate [Entactogenic drugs „ecstasy“ (MDMA), „eve“ (MDE) and other ringsubstituted methamphetamine derivatives. A new class of substances among illegal designer drugs?]. Eine neue Stoffklasse unter den illegalen Designerdrogen?. Nervenarzt 1996; 67: 369-80.
    PubMedGoogle Scholar
  • 8 Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 1986; 18: 305-13.
    CrossrefPubMedGoogle Scholar
  • 9 Simonsen KW, Kaa E. Designer drugs in Jutland. Ugeskr Laeger 2001; 163: 2248-52.
    PubMedGoogle Scholar
  • 10 Arimany J. et al. Intentional overdose and death with 3,4-methylenedioxyethamphetamine (MDEA; „Eve“): case report. Am J Forensic Med Pathol 1998; 19: 148-51.
    CrossrefPubMedGoogle Scholar
  • 11 Cole JC. et al. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002; 97: 1531-6.
    CrossrefPubMedGoogle Scholar
  • 12 Cox DE, Williams KR. „ADAM' or „EVE'?-a toxicological conundrum. Forensic Sci Int 1996; 77: 101-8.
    CrossrefPubMedGoogle Scholar
  • 13 Green AR. et al. The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, „Ecstasy“). Pharmacol Rev 2003; 55: 463-508.
    CrossrefPubMedGoogle Scholar
  • 14 Henderson GL. Designer drugs: past history and future prospects. J Forensic Sci 1988; 33: 569-75.
    PubMedGoogle Scholar
  • 15 Forsyth AJ, Barnard M, McKeganey NP. Musical preference as an indicator of adolescent drug use. Addiction 1997; 92: 1317-25.
    CrossrefPubMedGoogle Scholar
  • 16 Randall T. Ecstasy-fueled 'rave' parties become dances of death for English youths. Jama 1992; 268: 1505-6.
    CrossrefPubMedGoogle Scholar
  • 17 Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl) 1998; 139: 261-8.
    CrossrefPubMedGoogle Scholar
  • 18 Curran HV, Travill RA. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction 1997; 92: 821-31.
    PubMedGoogle Scholar
  • 19 Tossmann P, Boldt S, Tensil MD. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 2001; 7: 2-23.
    CrossrefPubMedGoogle Scholar
  • 20 Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64: 9-17.
    CrossrefPubMedGoogle Scholar
  • 21 Schechter MD. 'Candyflipping': synergistic discriminative effect of LSD and MDMA. Eur J Pharmacol 1998; 341: 131-4.
    CrossrefPubMedGoogle Scholar
  • 22 Glennon RA, Young R. MDMA stimulus generalization to the 5-HT(1A) serotonin agonist 8– hydroxy-2– (di-n-propylamino)tetralin. Pharmacol Biochem Behav 2000; 66: 483-8.
    CrossrefPubMedGoogle Scholar
  • 23 Lekskulchai V, Mokkhavesa C. Evaluation of Roche Abuscreen ONLINE amphetamine immunoassay for screening of new amphetamine analogues. J Anal Toxicol 2001; 25: 471-5.
    CrossrefPubMedGoogle Scholar
  • 24 Bundeszentrale für gesundheitliche Aufklärung (BZgA). Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2001. Eine Wiederholungsbefragung der Bundeszentrale für gesundheitliche Aufklärung, Endbericht. Köln: BzGA; 2001
    Google Scholar
  • 25 Simon R. et al. Bericht zur Drogensituation in Deutschland 2001 (Im Auftrag der Europäischen Beobachtungsstelle für Drogen und Drogensucht (EBDD) und des deutschen Bundesministeriums für Gesundheit (BMG)), Stand 1.12.2001: Deutsche Referenzstelle für die Europäische Beobachtungsstelle für Drogen und Drogensucht. 2001
    PubMedGoogle Scholar
  • 26 Johnston LD, O'Malley PM, Bachman JG. Monitoring the Future national results on adolescent drug use: Overview of key findings, 2002. (NIH Publication N. 03–5374). Bethesda, MD: National Institute on Drug Abuse; 2003
    Google Scholar
  • 27 Flüsmeier U, Rakete G. Konsummuster und psychosoziale Effekte des Konsums. In: Thomasius RH. editor. Ecstasy – Wirkungen, Risiken, Interventionen. Stuttgart: Enke; 1999: 83-95.
    Google Scholar
  • 28 Steele TD, Nichols DE, Yim GK. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 1987; 36: 2297-303.
    CrossrefPubMedGoogle Scholar
  • 29 Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 1988; 149: 159-63.
    CrossrefPubMedGoogle Scholar
  • 30 McKenna DJ, Guan XM, Shulgin AT. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5– hydroxytryptamine. Pharmacol Biochem Behav 1991; 38: 505-12.
    CrossrefPubMedGoogle Scholar
  • 31 Rudnick G, Wall SC. The molecular mechanism of „ecstasy“ [3,4-methylenedioxy- methamphetamine (MDMA)]: serotonin transporters are targets for MDMA- induced serotonin release. Proc Natl Acad Sci USA 1992; 89: 1817-21.
    CrossrefPubMedGoogle Scholar
  • 32 Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 2002; 95: 73-88.
    CrossrefPubMedGoogle Scholar
  • 33 Stone DM. et al. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4– methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986; 128: 41-8.
    CrossrefPubMedGoogle Scholar
  • 34 Stone DM, Johnson M, Hanson GR, Gibb JW. A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol 1987; 134: 245-8.
    CrossrefPubMedGoogle Scholar
  • 35 Schmidt CJ, Taylor VL. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. Eur J Pharmacol 1988; 156: 121-31.
    CrossrefPubMedGoogle Scholar
  • 36 Lyon RA, Glennon RA, Titeler M. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 1986; 88: 525-6.
    PubMedGoogle Scholar
  • 37 Pierce PA, Peroutka SJ. Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex. Neurosci Lett 1988; 95: 208-12.
    CrossrefPubMedGoogle Scholar
  • 38 Battaglia G, De Souza EB. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr 1989; 94: 240-58.
    PubMedGoogle Scholar
  • 39 Glennon RA. Phenylalkylamine stimulants, hallucinogens, and designer drugs. NIDA Res Monogr 1991; 105: 154-60.
    Google Scholar
  • 40 Hegadoren KM, Baker GB, Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 1999; 23: 539-53.
    CrossrefPubMedGoogle Scholar
  • 41 Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1: 273-7.
    PubMedGoogle Scholar
  • 42 Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of „Ecstasy“-related designer drugs. Biochem Pharmacol 2000; 59: 1563-71.
    CrossrefPubMedGoogle Scholar
  • 43 Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 2000; 112–113: 133-42.
    PubMedGoogle Scholar
  • 44 Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 2002; 24: 277-89.
    CrossrefPubMedGoogle Scholar
  • 45 Samyn N, De Boeck G, Wood M, Lamers CT, De Waard D, Brookhuis KA. et al. Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 2002; 128: 90-7.
    CrossrefPubMedGoogle Scholar
  • 46 Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J. et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4– methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136-45.
    PubMedGoogle Scholar
  • 47 Shulgin A, Shulgin A. PiKHAL. A chemical love story. Berkeley, CA: Transform Press; 1991
    Google Scholar
  • 48 de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN. et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 2000; 49: 104-9.
    PubMedGoogle Scholar
  • 49 Fallon JK. et al. Stereospecific analysis and enantiomeric disposition of 3,4– methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 1999; 45: 1058-69.
    PubMedGoogle Scholar
  • 50 Smilkstein MJ, Smolinske SC, Rumack BH. A case of MAO inhibitor/MDMA interaction: agony after ecstasy. J Toxicol Clin Toxicol 1987; 25: 149-59.
    CrossrefPubMedGoogle Scholar
  • 51 Tucker GT. et al. The demethylenation of methylenedioxymethamphetamine („ecstasy“) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47: 1151-6.
    CrossrefPubMedGoogle Scholar
  • 52 Wu D. et al. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997; 53: 1605-12.
    CrossrefPubMedGoogle Scholar
  • 53 Baggott M. et al. Chemical analysis of ecstasy pills. Jama 2000; 284: 2190.
    CrossrefPubMedGoogle Scholar
  • 54 Ramamoorthy Y. et al. Reduced (+/-)-3,4-methylenedioxymethamphetamine („Ecstasy“) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 2002; 63: 2111-9.
    CrossrefPubMedGoogle Scholar
  • 55 Hardman HF, Haavik CO, Seevers MH. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 1973; 25: 299-309.
    CrossrefPubMedGoogle Scholar
  • 56 Goad PT. Report: Acute and subacute oral toxicity study of methylenedioxymethamphetamine in rats. Protocol No. EMD-AT-001. Redfield, Arkansas: Intox Laboratory. (cited after Shulgin (1986)); 1985
    Google Scholar
  • 57 Ropero-Miller JD, Goldberger BA. Recreational drugs. Current trends in the 90s. Clin Lab Med 1998; 18 (04) 727-46.
    CrossrefPubMedGoogle Scholar
  • 58 Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with „ecstasy“ and „eve“ misuse. J Clin Pathol 1996; 49: 149-53.
    CrossrefPubMedGoogle Scholar
  • 59 Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-13.
    CrossrefPubMedGoogle Scholar
  • 60 Williams H. et al. „Saturday night fever“: ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 1998; 15: 322-6.
    CrossrefPubMedGoogle Scholar
  • 61 Schifano F. et al. Review of deaths related to taking ecstasy, England and Wales, 1997–2000. Bmj 2003; 326: 80-1.
    CrossrefPubMedGoogle Scholar
  • 62 Henry JA. Ecstasy and the dance of death. BMJ 1992; 305: 5-6.
    CrossrefPubMedGoogle Scholar
  • 63 Vollenweider-Scherpenhuyzen MFI, Vollenweider FX. Der Drogennotfall. Anaesthesist 1998; 47: 946-55.
    CrossrefPubMedGoogle Scholar
  • 64 Thomasius R. et al. AWMF-Behandlungsleitlinie: Psychische und Verhaltensstörungen durch Kokain, Amphetamine, Ecstasy und Halluzinogene [AWMF-Guideline: Cocaine-, Amphetamine-, Ecstasy- and Hallucinogen-Related Disorders.]. Fortschr Neurol Psychiatr 2004; 72: 679-95.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 65 Nowoczyn N. Designer-Drogen. In: Gölz J. (Ed.). Moderne Suchtmedizin. Stuttgart New York: Thieme; 1998. p. B 4.4 1-12.
    Google Scholar
  • 66 Moeller MR, Kraemer T. Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit 2002; 24: 210-21.
    CrossrefPubMedGoogle Scholar
  • 67 Ruangyuttikarn W, Moody DE. Comparison of three commercial amphetamine immunoassays for detection of methamphetamine, methylenedioxyamphetamine, methylenedioxymethamphetamine, and methylenedioxyethylamphetamine. J Anal Toxicol 1988; 12: 229-33.
    CrossrefPubMedGoogle Scholar
  • 68 Clauwaert KM. et al. Determination of the designer drugs 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxyethylamphetamine, and 3,4-methylenedioxyamphetamine with HPLC and fluorescence detection in whole blood, serum, vitreous humor, and urine. Clin Chem 2000; 46: 1968-77.
    PubMedGoogle Scholar
  • 69 Stout PR, Horn CK, Klette KL. Rapid simultaneous determination of amphetamine, methamphetamine, 3,4– methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, and 3,4– methylenedioxyethylamphetamine in urine by solid-phase extraction and GC-MS: a method optimized for high-volume laboratories. J Anal Toxicol 2002; 26: 253-61.
    CrossrefPubMedGoogle Scholar
  • 70 Jansen KL. Ecstasy (MDMA) dependence. Drug Alcohol Depend 1999; 53: 121-4.
    CrossrefPubMedGoogle Scholar
  • 71 Braida D, Sala M. Role of the endocannabinoid system in MDMA intracerebral self- administration in rats. Br J Pharmacol 2002; 136: 1089-92.
    CrossrefPubMedGoogle Scholar
  • 72 Hubner CB, Bird M, Rassnick S, Kornetsky C. The threshold lowering effects of MDMA (ecstasy) on brain-stimulation reward. Psychopharmacology 1988; 95: 49-51.
    PubMedGoogle Scholar
  • 73 Gold LH, Hubner CB, Koob GF. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology 1989; 99: 40-7.
    CrossrefPubMedGoogle Scholar
  • 74 Fischer C. et al. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, „ecstasy“). J Neurosci 1995; 15: 5476-85.
    CrossrefPubMedGoogle Scholar
  • 75 O'Loinsigh ED. et al. Behavioural, hyperthermic and neurotoxic effects of 3,4– methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 621-38.
    CrossrefPubMedGoogle Scholar
  • 76 Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 1992; 648: 371-82.
    CrossrefPubMedGoogle Scholar
  • 77 Ricaurte GA. et al. 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. Eur J Pharmacol 1987; 137: 265-8.
    CrossrefPubMedGoogle Scholar
  • 78 Parrott AC. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002; 71: 837-44.
    CrossrefPubMedGoogle Scholar
  • 79 McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4– methylenedioxymethamphetamine ('Ecstasy'). Br J Psychiatry 1994; 165: 391-5.
    CrossrefPubMedGoogle Scholar
  • 80 Schifano F, Magni G. MDMA („ecstasy“) abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry 1994; 36: 763-7.
    CrossrefPubMedGoogle Scholar
  • 81 Cohen RS. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; „Ecstasy“). Biol Psychiatry 1996; 39: 819-20.
    CrossrefPubMedGoogle Scholar
  • 82 Creighton FJ, Black DL, Hyde CE. 'Ecstasy' psychosis and flashbacks. Br J Psychiatry 1991; 159: 713-5.
    CrossrefPubMedGoogle Scholar
  • 83 McGuire P, Fahy T. Flashbacks following MDMA. Br J Psychiatry 1992; 160: 276.
    PubMedGoogle Scholar
  • 84 McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA („ecstasy“). Bmj 1991; 302: 697.
    Google Scholar
  • 85 McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 1991; 11: 302-5.
    PubMedGoogle Scholar
  • 86 Windhaber J, Maierhofer D, Dantendorfer K. Panic disorder induced by large doses of 3,4– methylenedioxymethamphetamine resolved by paroxetine. J Clin Psychopharmacol 1998; 18: 95-6.
    CrossrefPubMedGoogle Scholar
  • 87 Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32: 91-5.
    CrossrefPubMedGoogle Scholar
  • 88 Haddad PM, Strickland P, Anderson I, Deakin JF, Dursun SM. Effects of MDMA (ecstasy) use and abstention on serotonin neurons. Lancet 2002; 359: 1616-7 author reply 1617–8.
    CrossrefPubMedGoogle Scholar
  • 89 Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA („ecstasy“) RETRACTED. Science 2002; 297: 2260-3.
    CrossrefPubMedGoogle Scholar
  • 90 Ricaurte GA. et al. Retraction of „Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA („ecstasy“). Science 2003; 301: 1479.
    PubMedGoogle Scholar
  • 91 Anonynous. Ecstasy's after-effects. Nature 2003; 425: 223.
    Google Scholar
  • 92 Knight J. Agony for researchers as mix-up forces retraction of ecstasy study. Nature 2003; 425: 109.
    CrossrefPubMedGoogle Scholar
  • 93 Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process?. Am J Psychother 1986; 40: 393-404.
    PubMedGoogle Scholar
  • 94 Doblin R. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs 2002; 34: 185-94.
    CrossrefPubMedGoogle Scholar
  • 95 Sondermann N, Kovar KA. Screening experiments of ecstasy street samples using near infrared spectroscopy. Forensic Sci Int 1999; 106: 147-56.
    CrossrefPubMedGoogle Scholar
  • 96 Loor R, Lingenfelter C, Wason PP, Tang K, Davoudzadeh D. Multiplex assay of amphetamine, methamphetamine, and ecstasy drug using CEDIA technology. JAnal Toxicol 2002; 26: 267-73.
    Google Scholar
  • 97 Bell SE, Burns DT, Dennis AC, Speers JS. Rapid analysis of ecstasy and related phenethylamines in seized tablets by Raman spectroscopy. Analyst 2000; 125: 541-4.
    CrossrefPubMedGoogle Scholar
  • 98 Winstock AR, Wolff K, Ramsey J. Ecstasy pill testing: harm minimization gone too far?. Addiction 2001; 96: 1139-48.
    CrossrefPubMedGoogle Scholar
  • 99 Stephenson CP, Hunt GE, Topple AN, McGregor IS. The distribution of 3,4-methylenedioxymethamphetamine „Ecstasy“-induced c-fos expression in rat brain. Neuroscience 1999; 92: 1011-23.
    CrossrefPubMedGoogle Scholar
  • 100 Vollenweider FX. et al. Psychological and cardiovascular effects and short-term sequelae of MDMA („ecstasy“) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241-51.
    CrossrefPubMedGoogle Scholar
  • 101 Aalberg L. et al. Chromatographic and mass spectral methods of identification for the side-chain and ring regioisomers of methylenedioxymethamphetamine. J Chromatogr Sci 2000; 38: 329-37.
    CrossrefPubMedGoogle Scholar
  • 102 Brunnenberg M. et al. Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl 1998; 719: 79-85.
    CrossrefPubMedGoogle Scholar
  • 103 Tehan B, Hardern R, Bodenham A. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ('Eve'). Anaesthesia 1993; 48: 507-10.
    CrossrefPubMedGoogle Scholar